These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 12531932)

  • 1. Measuring motor complications in clinical trials for early Parkinson's disease.
    Marras C; Lang AE
    J Neurol Neurosurg Psychiatry; 2003 Feb; 74(2):143-6. PubMed ID: 12531932
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimising levodopa therapy for the management of Parkinson's disease.
    Stocchi F
    J Neurol; 2005 Oct; 252 Suppl 4():IV43-IV48. PubMed ID: 16222437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review.
    Pahwa R; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S35-52. PubMed ID: 15501365
    [No Abstract]   [Full Text] [Related]  

  • 5. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
    Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease.
    Manson AJ; Iakovidou E; Lees AJ
    Mov Disord; 2000 Mar; 15(2):336-7. PubMed ID: 10752589
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic dilemma: psychosis and Parkinson's disease.
    Damecour CL; Turcotte JR
    Can J Psychiatry; 1995 Dec; 40(10):640-1. PubMed ID: 8681265
    [No Abstract]   [Full Text] [Related]  

  • 10. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
    Arnold G; Trenkwalder C; Schwarz J; Oertel WH
    Mov Disord; 1994 Mar; 9(2):238-40. PubMed ID: 7910949
    [No Abstract]   [Full Text] [Related]  

  • 11. Is levodopa toxic?
    Weiner WJ
    Arch Neurol; 2000 Mar; 57(3):408-10. PubMed ID: 10714671
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacotherapy of Parkinson's disease].
    Ceballos-Baumann A
    MMW Fortschr Med; 2013 May; 155(8):49-51. PubMed ID: 24437138
    [No Abstract]   [Full Text] [Related]  

  • 13. Rasagiline for motor complications in Parkinson's disease.
    Clarke CE
    Lancet; 2005 Mar 12-18; 365(9463):914-6. PubMed ID: 15766976
    [No Abstract]   [Full Text] [Related]  

  • 14. Why delaying levodopa is a good treatment strategy in early Parkinson's disease.
    Olanow CW; Stocchi F
    Eur J Neurol; 2000 May; 7 Suppl 1():3-8. PubMed ID: 11054152
    [No Abstract]   [Full Text] [Related]  

  • 15. [Practical Use of the Levodopa Pump].
    Südmeyer M; Ebersbach G; Holtmann M; Jost W; Odin P; Schrader C; Winkler C
    Fortschr Neurol Psychiatr; 2016 Jul; 84(7):404-10. PubMed ID: 27471998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Chaudhuri KR; Jenner P; Antonini A
    Mov Disord; 2019 Jun; 34(6):816-819. PubMed ID: 30983023
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy for patients with progressive Parkinson's disease].
    Murata M
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1432-7. PubMed ID: 13677891
    [No Abstract]   [Full Text] [Related]  

  • 19. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The initial treatment of Parkinson's disease.
    Factor SA
    Mov Disord; 2000 Mar; 15(2):360-1. PubMed ID: 10752599
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.